Gerald Lema's insider trading at FibroGen
SEC Form 4 filings for Lema Gerald, 409 Illinois St, San Francisco, CA 94158, USA

Insider trading of Gerald Lema, a Director at FGEN FibroGen, Inc

Most recently Gerald Lema bought 3,500 shares worth $163,450.00 on 4 December 2017.

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2017-12-04 Gerald Lema
Director
Director Buy 3,500 $46.70 $163,450.00
2017-12-04
3,500 SEC insider form 4
FibroGen, Inc logo

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

  • FibroGen, Inc, 409 Illinois Street, San Francisco 94158, United States
  • fibrogen.com
  • 415-978-1200
Messenger